SPONSOR
JIANG LONGWEI
Total Trials
2
Recruiting
2
Phases
EARLY_Phase 1
Conditions studied: GliomasDC-CIK TreatmentRegorafenibColorectal CancerImmune Combination TherapyIparomlimab and Tuvonralimab Injection
JIANG LONGWEI is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Gliomas, DC-CIK Treatment, Regorafenib, Colorectal Cancer.
The trial portfolio spans EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — JIANG LONGWEI
How many clinical trials has JIANG LONGWEI sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by JIANG LONGWEI, of which 2 are actively recruiting participants. These trials cover conditions including Gliomas, DC-CIK Treatment, Regorafenib. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does JIANG LONGWEI research focus on?
JIANG LONGWEI clinical trials span Gliomas, DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy, and additional conditions. The research pipeline includes EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a JIANG LONGWEI clinical trial?
To participate in a JIANG LONGWEI trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all JIANG LONGWEI trials with current recruitment status updated daily.
Clinical Trials by JIANG LONGWEI
NCT06828341 EARLY_Phase 1
Recruiting
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
Gliomas
NCT07343791 EARLY_Phase 1
Recruiting
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
DC-CIK Treatment
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology